Reflections on FDA Draft Guidance on Bayesian Methods in Trials—Protecting Scientific Integrity and Evidentiary Standards

JAMA 2026 Open access

Read full text
Authors: Scott R. Evans, Thomas R. Fleming, Holly Janes, Lori E. Dodd
DOI: 10.1001/jama.2026.4175
Cited by: 3
References: 8

Abstract

This Perspective discusses the use of bayesian methods in clinical trials and the importance of having US Food and Drug Administration (FDA) guidance that provides substantive insights about the methods’ proper role.

Fields of Study & Subjects

Statistical Methods in Clinical Trials Meta-analysis and systematic reviews Ethics in Clinical Research

Publication details

Journal / source
JAMA
Publisher
American Medical Association (AMA)
Volume
335
Issue
19
Pages
1659–1659
Publication date
23 March 2026
Language
EN